Core Viewpoint - The company has entered into a conditional equity transfer agreement to sell a 49% stake in Shanghai Shanshi Medical Beauty Hospital Co., Ltd. for a total consideration of RMB 73.598 million, which aligns with its strategy to optimize asset allocation and focus on core business development [1] Group 1: Transaction Details - The agreement involves Shanghai Huashi and Shanghai Lingfeng Medical, with Shanghai Lingfeng Medical agreeing to purchase the stake from Shanghai Huashi and the company's wholly-owned subsidiary, Shanghai Dajiankang Management [1] - Upon completion of the transaction, the company will no longer hold any equity in the target company, which will be fully owned by Shanghai Lingfeng Medical [1] Group 2: Strategic Implications - The sale allows the company to recover and reallocate capital, streamline its investment portfolio, and concentrate resources on its main business, thereby enhancing operational efficiency and capital discipline [1] - This transaction is part of the company's ongoing strategy to improve cash flow and support long-term sustainable growth [1]

Group 1 - The target company is owned by Shanghai Lingfeng Medical (51%), Shanghai Huashi (30%), and Shanghai Dasheng Management (19%), with the group holding a 19% indirect interest classified as an investment in an associate [1] - Following the completion of the transaction, the company will no longer hold any interest in the target company, which will be wholly owned by Shanghai Lingfeng Medical, and the target company will cease to be an associate of the company [1] - The group aims to recover and reallocate capital through the sale, streamline its investment portfolio, and focus resources on core business operations to enhance operational efficiency and capital discipline [1] Group 2 - Shanghai Dasheng Management, a wholly-owned subsidiary of the company, has entered into a conditional equity transfer agreement with Shanghai Huashi and Shanghai Lingfeng Medical to sell a combined 49% stake in the target company, Shanghai Shanshi Medical Beauty Hospital Co., Ltd., for a total consideration of RMB 73.598 million [2]

Core Viewpoint - The company is divesting its 19% stake in Shanghai Shanshi Medical Beauty Hospital to streamline its investment portfolio and focus on core business operations, enhancing operational efficiency and capital discipline [1] Group 1: Transaction Details - The company’s wholly-owned subsidiary, Shanghai Shanshi Urban Development, entered into a conditional equity transfer agreement on November 13, 2025, with Shanghai Huashi and Shanghai Lingfeng Medical [1] - The total consideration for the 49% stake in the target company is RMB 73.598 million [1] - Post-transaction, the target company will be wholly owned by Shanghai Lingfeng Medical, and the company will no longer hold any equity in it [1] Group 2: Strategic Implications - The divestment allows the company to recover and reallocate capital, streamline its investment portfolio, and concentrate resources on its main business [1] - This move aligns with the company's strategy to optimize asset allocation, improve cash flow, and focus on core business development [1] - The transaction is expected to support the company in achieving long-term sustainable growth [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：563） 關連交易 出售於聯營公司之股權 出售事項 董事會宣佈，上實城開上海大健康管理於二零二五年十一月十三日與上海華氏及 上海凌風醫療訂立股權轉讓協議，據此，上海華氏及上實城開上海大健康管理有 條件同意出售而上海凌風醫療有條件同意購買有關股權，合共佔目標公司之 49%，總代價為人民幣73,598,000元。 於本公告日期，目標公司由上海凌風醫療、上海華氏及上實城開上海大健康管理 分別擁有51%、30%及19%。本集團於目標公司之19%間接權益，在本公司綜合 財務報表中分類為於聯營公司之投資。完成後，本公司將不再擁有目標公司之任 何權益，目標公司將由上海凌風醫療全資擁有。目標公司將不再為本公司之聯營 公司。 上市規則之涵義 於本公告日期，(i)上海凌風醫療為本公司控股股東上實集團之全資附屬公司； 及(ii)上海華氏為上海醫藥（集團）之全資附屬公司，上海醫藥（集 ...

Group 1 - The company, Shanghai Urban Development (00563.HK), announced the appointment of executive director Zhou Yadong and independent non-executive director Chen Haohua as members of the nomination committee, effective from November 12, 2025 [1]

上实城市开发(00563)发布公告，公司执行董事周亚栋女士及独立非执行董事陈浩华博士已获委任为公 司提名委员会的成员，自2025年11月12日起生效。 ...

上海實業城市開發集團有限公司（「本公司」）董事（「董事」）會（「董事會」）現共有七名 董事，每名董事的姓名、角色和職能載列如下： 執行董事 黃海平先生 （主席） 李忠輝先生 （總裁） 周亞棟女士 獨立非執行董事 杜惠愷先生， B.B.S.，太平紳士 范仁達博士 李家暉先生， M.H 陳浩華博士 （於百慕達註冊成立之有限公司） （股份代號：563） 董事名單與其角色和職能 本公司已設立四個董事委員會，並制定有關職權範圍。下表提供各董事會成員於各 董事委員會所擔任的職務。 | | 董事委員會 | 審核 | 提名 | 薪酬 | 投資評證 | | --- | --- | --- | --- | --- | --- | | 董事 | | 委員會 | 委員會 | 委員會 | 委員會 | | 黃海平先生 | | | C | | | | 李忠輝先生 | | | | | M | | 周亞棟女士 | | | M | | M | | 杜惠愷先生， | B.B.S.，太平紳士 | M | M | C | | | 范仁達博士 | | M | M | M | C | | 李家暉先生， | M.H | C | | | | | 陳浩華博士 ...

上述委任乃因應香港聯合交易所有限公司證券上市規則（「上市規則」）及上市規則附 錄C1所載企業管治守則之修訂而作出，該等修訂已於二零二五年七月一日生效。董 事會相信，實施上述委任將加強董事會之效率及多元化，並進一步提升本公司之整 體良好企業管治常規。 董事會謹藉此機會歡迎周亞棟女士及陳浩華博士加入提名委員會。 承董事會命 上海實業城市開發集團有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或倚賴該等內容而引致之任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：563） 委任提名委員會成員 上海實業城市開發集團有限公司（「本公司」）之董事（「董事」）會（「董事會」）謹此宣 佈，本公司執行董事周亞棟女士及獨立非執行董事陳浩華博士已獲委任為本公司提 名委員會（「提名委員會」）之成員，自二零二五年十一月十二日起生效。 於上述委任後，提名委員會由五位成員組成，即黃海平先生（ 委員會主席 ）、周亞棟 女士、杜惠愷先生， B.B.S.，太平紳士 、范仁達博士及陳浩華博士。提名委員會現已 ...

Core Viewpoint - The company, Shanghai Urban Development (00563), has successfully issued corporate bonds totaling up to RMB 1.15 billion, aimed at refinancing existing debt obligations [1] Group 1: Bond Issuance Details - The bonds were issued by the company's subsidiary, Shanghai Chengkai (Group) Co., Ltd., on November 6, 2025 [1] - The issuance consists of two types of bonds: (i) a three-year bond with a total principal of RMB 950 million and an interest rate of 2.08%, and (ii) a five-year bond with a total principal of RMB 200 million and an interest rate of 2.56% [1] - All bonds were issued through an offline book-building process targeted at professional institutional investors [1] Group 2: Use of Proceeds - The proceeds from the bond issuance will be used entirely to refinance the principal of maturing corporate bonds with the company's own funds [1]

Core Viewpoint - Shanghai Urban Development (00563) has successfully issued corporate bonds totaling up to RMB 1.15 billion, aimed at refinancing maturing debt [1] Group 1: Bond Issuance Details - The bonds were issued by Shanghai Chengkai (Group) Co., Ltd., a subsidiary of the company, on November 6, 2025 [1] - The issuance includes two types of bonds: (i) a three-year bond with a total principal of RMB 950 million and an annual interest rate of 2.08%, and (ii) a five-year bond with a total principal of RMB 200 million and an annual interest rate of 2.56% [1] - All bonds were issued through an offline book-building process targeted at professional institutional investors [1] Group 2: Use of Proceeds - The funds raised from the bond issuance will be used entirely for the replacement and repayment of maturing corporate bond principal from the company's own funds [1]